Cor­rect­ed: Roche is not mov­ing for­ward with SQZ pro­gram, send­ing the biotech in­to strate­gic re­view

This sto­ry was cor­rect­ed to note that Roche has elect­ed not to take its op­tion on SQZ’s pro­gram. A pre­vi­ous ver­sion said that Roche and SQZ had end­ed their part­ner­ship. This sto­ry was al­so up­dat­ed with up­front and near-term pay­ment in­for­ma­tion.

Roche is walk­ing away from its col­lab­o­ra­tion on SQZ Biotech­nolo­gies’ clin­i­cal pro­gram.

Roche de­cid­ed not to li­cense and de­vel­op SQZ’s anti­gen pre­sent­ing cells (APCs) that are de­signed to spark killer T cells to go af­ter HPV16-pos­i­tive can­cers, the biotech an­nounced Tues­day morn­ing. The pro­gram is SQZ’s on­ly APC in the clin­ic, which it is test­ing in a Phase I/II study in pa­tients with head and neck, cer­vi­cal, anal, vul­var, or pe­nile can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER